(Q83461364)
Statements
A 2-year post-authorization safety study of high-strength pancreatic enzyme replacement therapy (pancreatin 40,000) in cystic fibrosis (English)
James M Littlewood
Suntje Sander-Struckmeier
Friederike Henniges
Creon 40,000 Study Group